BUZZ-Hikma: bottom of STOXX as generic Advair faces US delay, 2017 approval unlikely

** Drugmaker Hikma down 8 pct, bottom of Stoxx 600 , with its partner Vectura -9%

** Hikma says US regulators have decided not to approve its generic copy of GlaxoSmithKline (Other OTC: GLAXF - news) 's blockbuster lung drug Advair at this time, due to 'major' issues with its application, co says

** Low likelihood of approval this year, co adds

** GlaxoSmithKline, which is trading ex-dividend on Thursday, -0.1%

** Hikma also biggest faller on UK's FTSE 100, while Vectura is bottom of the FTSE 250, both in strong volume

** Shares (Berlin: DI6.BE - news) in Hikma & Vectura both fell on Wednesday on speculation of FDA 'no' for generic Advair, -1.2% and 3.3%, respectively

(RM (LSE: RM.L - news) :sanjeeban.sarkar.thomsonreuters.com@reuters.net)